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ABSTRACT
Objective To evaluate objective and subjective outcomes 
after bilateral implantation of two different multifocal 
intraocular lenses, which correct pseudophakic presbyopia 
in an adequate and homogeneous population court.
Methods and analysis Fifty patients were evaluated 
at 3 months after bilateral implantation, at the Eye Clinic 
of University of Verona and at the Carones Ophthalmology 
Center Milano, as follows: Tecnis Symfony (25 patients), 
Alcon PanOptix (25 patients). Main outcomes were 
uncorrected and best- corrected distance visual acuity 
(UDVA and BCVA) at 4 m, 60 cm (best distance corrected 
intermediate visual acuity (BDCIVA) and uncorrected 
intermediate visual acuity), 40 cm (best distance corrected 
near visual acuity (BDCNVA) and uncorrected near visual 
acuity (UNVA)), objective refractive outcome, defocus 
curve, contrast sensitivity (Modulation Transfer Function 
(MTF) cut- off), optical quality (Strehl ratio), aberrometry 
(root mean square RMS 4 mm), subjective quality of life 
(National Eye Institute Refractive Error Quality of Life score 
(NEI- RQL-42 score) test).
Results Symfony and PanOptix showed BCVA and UDVA 
comparable results. Symfony presented significant better 
outcomes at BDCIVA (p=0.001), while PanOptix showed 
better performances at BDCNVA and UNVA (p=0.01). 
Symfony achieved better results in RMS 4 mm (p=0.024) 
and in MTF cut- off (p=0.041). In the questionnaire NEI- 
RQL-42, PanOptix presented better scores in ‘near vision’ 
and ‘spectacles independence’, whereas Symfony in 
‘symptoms’ and ‘clarity of vision’.
Conclusion Both intraocular lenses are valid options to 
avoid pseudophakic presbyopia, even though they present 
different features which make them unique. Symfony 
allows patients to achieve a better objective and subjective 
quality of vision and contrast sensitivity; PanOptix 
provides better outcomes in near vision and spectacles 
independence requirements.
INTRODUCTION
Multifocal intraocular lenses (MIOLs) were 
designed to improve spectacle independence, 
but this advantage was balanced with a low 
quality of vision at near and far distances due 
to the presence of contrast sensitivity (CS) 
function deterioration and subjective symp-
toms such as halos and glare.1–3 Currently, 
the majority of new generation MIOLs 
improve these defects and present a diffrac-
tive platform that splits lights to the retina, 
in order to obtain a good quality image at 
several distances and achieve a good spec-
tacle independence.4 5 Nowadays, modern 
MIOLs obtain multifocality, thanks to two 
different diffractive technologies which are 
extended range of vision (ERV) that is used 
by Tecnis Symfony and Enlighten technology 
(Enlighten Optical Technology) that is 
exploited by PanOptix.6 7 Several studies have 
been carried out on these MIOLs, but the 
literature present discordant results on visual 
Key messages
What is already known about this subject?
 ► In literature there is no consensus on Symfony and 
Pan0ptix performances in intermediate distance dis-
tance visual acuity anda quality of vision outcomes. 
Non- concordant data are due to the small and to dif-
ferent conditions in the quality of vision evaluation.
What are the new findings?
 ► This prospective study is the first which gatered 
the largest and well- balanced cohort of patients, to 
shed the light on these two presbyopia- correcting 
intraocular lenses (IOLs), focusing on visual acuity at 
intermediate and near distances and on the quality 
of vision.
How might these results change the focus of 
research or clinical practice?
 ► This study allows the surgeon and the patient to cus-
tomise the surgical intervention choosing the specif-
ic implant compatible with patient's need, proving 
that Pan0ptix IOL would be an optimal choice for 
patients who wish to see optimally at near range, 
















phth: first published as 10.1136/bm





2 Pedrotti E, et al. BMJ Open Ophth 2020;5:e000497. doi:10.1136/bmjophth-2020-000497
Open access
acuity at intermediate distances, defocus curve and on the 
quality of vision.8–12 The aim of the study is to compare 
these modern MIOLs (Tecnis Symfony ERV ZXR00 IOL 
and Acrysof IQ PanOptix TNFT00) in order to obtain 
objective and subjective analysis which provides clarity, 
thus helping the surgeon to choose the most appropriate 
IOL for the patient.
MATERIALS AND METHODS
Study design
This prospective observational comparative clinical 
study included patients after bilateral implantation 
of Tecnis Symfony or Acrysof IQ PanOptix for routine 
clinical practice. All patients were included at the Depart-
ment of Neurosciences, Biomedicine and Movement 
Sciences, Eye Clinic, University of Verona, Verona, and 
at the Carones Ophthalmology Center, Milano, Italy. The 
calculation of the sample size was based on the primary 
outcomes of Best Corrected Distance Intermediate Visual 
Acuity (BCDIVA) at 60 cm under photopic condition and 
Best Corrected Distance Visual Acuity (BCDVA) at 40 cm.
The sample size of 50 subjects (25 for each group) 
reaches a power equal to 95% capable of detecting a differ-
ence between the averages of BCDIVA equal to 0.006 with 
SD 0.04 in the Symfony group and 0.07 in the PanOptix 
group with an alpha significance level of 0.05 using the 
T test for independent sample.8–12 The sample size was 
calculated with PASS V.14 software, in order to obtain a 
valid statistical analysis.9–11 13 14 Twenty- five consecutive 
patients were prospectively recruited the day after the 
implantation of the second eye with the Tecnis Symfony 
IOL (Symfony group) and 25 consecutive patients were 
prospectively enrolled the day after the implantation 
of the second eye with the Acrysoft IQ PanOptix IOL 
(PanOptix group), being careful to enrol patients who 
respected inclusion criteria and in order to create two 
homogeneous group for age and ocular parameters with 
a randomisation of 1:1. For routine clinical practice, each 
patient underwent surgery in the second eye 1 week after 
the first. All patients enrolled in the study were informed 
and written informed consent was obtained. The study 
adhered to the tenets of the Declaration of Helsinki and 
was notified to the local ethical committee (Department 
of Neuroscience, Biomedicine and Movement Sciences, 
University of Verona).
Only the investigators carrying out the follow- ups were 
masked to the implanted IOLs. Neither surgery treat-
ment nor outcomes were masked.
Patient and public involvement statement
This study was done without patient or public involve-
ment. Patients were not invited to discuss on the study 
design or interpret the results. Patients were not asked to 
contribute to the writing or editing of this paper.
Patients’ choice
Inclusion criteria for the study were patients with bilateral 
IOL implantation (Tecnis Symfony IOL, or Acrysoft IQ 
PanOptix IOL) with a pre- existing corneal astigmatism 
within 1.00 D and axial length between 22.0 mm and 24.5 
mm before surgery. Exclusion criteria included patients 
with intraoperative complications, previous ocular 
surgery including corneal, retinal or refractive surgery, 
previous ocular trauma, and any ocular disease such as 
amblyopia, chronic or recurrent uveitis, acute ocular 
disease, diabetes mellitus with retinal changes, glaucoma, 
pseudoexfoliation syndrome or zonular laxity, optic 
nerve atrophy, keratoconus, alteration in colour percep-
tion and corneal endothelial dystrophy. All patients were 
evaluated at the baseline (1 day after the surgery), 1 week, 
1 month and 3 months after the baseline, but all results 
reported refer to the 3- month follow- up visit.
Surgical technique
All included patients previously underwent a standard 
sutureless phacoemulsification surgery without any intra-
operative complications. The surgery was performed by 
two experienced surgeons (EP, FC). In all cases, topical 
anaesthesia was administered and pharmacological 
mydriasis was induced using a combination of cyclopen-
tolate 1.0% and phenylephrine 0.1%. IOL power and 
predicted postoperative refraction were calculated with 
a Lenstar Optical Biometer (Haag- Streit, USA), using 
SRK/T biometry for all eyes (between 22.00 mm and 
24.5 mm). IOL dioptric power was selected targeting 
emmetropia, using the IOL power corresponding to 0 or 
to the negative (myopic) predicted refractive outcome 
closest to 0. At baseline all patients received the same 
postoperative medication, which was a combination of 
topical netilmicin 0.3% and dexamethasone 0.1% four 
times a day for 2 weeks and then tapered off by one drop 
per week. Likewise, non- steroidal anti- inflammatory 
diclofenac 0.1% drops were prescribed three times a day 
for 4 weeks to prevent macular oedema.
Intraocular lens (IOL)
Tecnis Symfony ZXR00 is an ERV IOL that is distrib-
uted by Johnson & Johnson (Johnson & Johnson, New 
Brunswick, New Jersey, USA). It is a UV blocking hydro-
phobic acrylic, single piece IOL, aspheric in the anterior 
surface and achromatic diffractive in the posterior one. 
Unlike diffractive MIOLs which split the light in different 
discrete foci, Symfony technology elongates the depth 
of focus, thanks to echelette design, and it is character-
ised by a typical continuum range of foci that induces 
a defocus curve with a single large peak. Moreover, 
Symfony technology includes a compensation for positive 
corneal spherical aberration which allows to achieve a 
better quality of vision. In this IOL it has been calculated 
that light transmission to the retina reaches 92%.6
Acrysof IQ PanOptix TNFT00 is a tri- quadrifocal IOL 
that is distributed by Alcon (Alcon Laboratories, Inc, Fort 
Worth, Texas, USA). It is a hydrophobic acrylic, single 
piece, aspheric non- apodised diffractive IOL. PanOptix 
design presents four focal points (40 cm, 60 cm, 120 cm and 
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the light energy for intermediate focal point (120 cm) is 
redistributed to the infinity focal point, in order to obtain 
better performances in the distance (Enlighten Optical 
Technology). For this reason, patients with PanOptix IOLs 
could only use three focal points: at distance, at 60 cm and 
at 40 cm. Light entering the eye is distributed 50% for far 
distance focus, 25% for near distance focus and 25% for 
intermediate distance focus, with a total transmission of 
88% of light to the retina with a pupil diameter of 3.0 mm.7
Outcomes
Monocular visual acuity, corrected for distance and uncor-
rected were measured using the corresponding Early 
Treatment Diabetic Retinopathy Study (ETDRS) chart 
under photopic conditions (683 lm/W) and 100% contrast 
(ESV-3000 ETDRS System, Vectorvision, Inc) at 4 m.
To obtain the defocus curve, binocular visual perfor-
mances were tested under photopic conditions (683 lm/W) 
and 100% contrast (ESV-3000 ETDRS System, Vectorvision, 
Inc) at 4 m. Each patient was corrected for distance acuity 
in both eyes and additional lenses were added sequenced 
over the range of +1.00 to −4.00 D in 0.50 D steps, recording 
visual acuity for each step. In order to avoid memory effects 
presenting letter sequences were randomised and patient’s 
eyes were occluded between each lens presentation, so that 
the subject was not aware of which lens had been inserted 
and whether the letter on the chart had been changed or 
not.8
Intermediate and near visual acuity were measured 
monocular, respectively, at 60 cm and 40 cm using 
ETDRS near acuity charts (Sloan ETDRS format near 
vision, precision vision) with 100% contrast and photopic 
condition (683 lm/W).
Objective quality of vision was measured with objective 
CS (MTF cut- off) and objective optical quality (Strehl 
ratio), calculated with Optical Quality Analysis System 
(OQAS, Visiometrics SL, Terassa, Spain).
Aberrometry (root mean square, RMS 4 mm) was 
calculated with Hartmann- Shack aberrometer (Topcon, 
Tokyo, Japan).
Last, the subjective quality of vision was evaluated using 
the National Eye Institute Refractive Error Quality of Life 
score test (NEI- RQL-42 score), and in particular we focused 
our attention on subscales of ‘clarity of vision’, ‘near vision’, 
‘dependence on correction’ and ‘symptoms’.
Statistical analysis
Data analysis was performed using SPSS for Windows 
software (V.19.0, IBM Corporation, Armonk, New York, 
USA). Normality of data samples was evaluated using the 
Kolmogorov- Smirnov test. When parametric analysis was 
possible, the Student’s test for unpaired data was used for 
comparison between IOLs, whereas the Mann- Whitney test 
was used when parametric analysis was not possible. A p value 
<0.05 was considered statistically significant.
RESULTS
The study comprised 50 patients (100 eyes) of whom 25 
patients had Symfony IOLs and 25 patients had PanOptix 
IOLs implanted. There were no preoperative statistically 
significant differences between the two groups in terms 
of age, corneal keratometry and pupil diameter (phot-
opic and scotopic conditions, table 1). No patient was 
lost during follow- up period, there were no postoperative 
complications or adverse effect.
Visual acuity
Symfony and PanOptix groups showed comparable 
results in objective refraction: postoperative SE was −0.02 
(±0.48) D in the Symfony group and –0.1 (±0.42) D in 
the PanOptix group, without any statistically significant 
difference between the two groups. Mean uncorrected 
distance visual acuity (UDVA) measured at 4 m was 0.00 
(±0.09) logMar for the Symfony group and −0.02 (±0.09) 
logMar for the PanOptix group. Mean best distance 
corrected visual acuity (BDCVA) measured at 4 m was 
−0.09 (±0.05) logMar for the Symfony group and −0.08 
(±0.06) logMar for the PanOptix group. No statistically 
significant difference in mean values was found between 
groups both concerning UDVA (p=0.272) and BDCVA 
(p=0.489, table 2).
Mean monocular uncorrected intermediate visual 
acuity (UIVA) measured at 60 cm was 0.10 (±0.03) 
logMar for the Symfony group and 0.12 (±0.04) logMar 
for the PanOptix group. Mean best distance corrected 
intermediate visual acuity (BDCIVA) measured at 60 cm 
was 0.07 (±0.03) logMar for the Symfony group and 0.10 
(±0.03) logMar for the PanOptix group. No statistically 
significant difference in mean values was found between 
groups both concerning UIVA (p=0.058), however the 
difference in BDCIVA achieved statistical significance 
(p=0.001) with the better outcome in favour of the 
Symfony group.
Table 1 Preoperative patient’s characteristics in the two 
IOL groups
Sample features before surgery
P value
Extended Depth 
of Focus IOL 
mean (SD) (25 
patients)
Enlighten IOL 
mean (SD) (25 
patients)
Age (years), mean (SD) 70.16±4.4 72.12±3.25 >0.05




AL (mm), mean (SD) 23.21±1.2 23.87±2.5 >0.05
K1 (D), mean (SD) 43.99±1.88 43.17±3.8 >0.05
K2 (D), mean (SD) 44.41±3.25 43.87±1.3 >0.05
IOL power (D), mean 
(SD)
21.83±4.5 21.02±2.86 >0.05
Photopic pupil size 
(mm), mean (SD)
3.28±0.3 3.16±0.20 >0.05
Scotopic pupil size 
(mm), mean (SD)
5.02±0.4 5.11±0.3 >0.05
AL, Axial Lenght; CDVA, Corrected Distance Visual Acuity; EDOF, 
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Mean monocular uncorrected near visual acuity (UNVA) 
and mean monocular best distance corrected near visual 
acuity (BDCNVA) measured at 40 cm were, respectively, 0.26 
(±0.08) logMar and 0.26 (±0.05) logMar for the Symfony 
group, whereas 0.14 (±0.045) logMar and 0.14 (±0.04) 
logMar for the PanOptix group. The difference both in 
mean UNVA and mean BDCNVA between groups achieved 
statistical significance (respectively p=0.001 and p=0.001) 
with the better outcome in favour of the PanOptix group.
Defocus curve
Both groups showed a reduction in visual acuity as nega-
tive defocus increased. Both groups showed similar mean 
BDCVA without statistically significant differences (p=0.489). 
The Symfony IOL showed a ‘softer’ decrease in visual acuity 
as negative defocus increased when compared with the 
PanOptix group that showed a ‘bifocal’ defocus profile 
(figure 1). The difference in mean BDCVA acquired statis-
tical significance at −1.50 D defocus threshold (p=0.006) with 
Table 2 Visual acuity at several distances at 3 months after bilateral implantation
Postoperative visual acuity





Median (range) P value
BCDVA 4 m 0.489
Mean±SD −0.09 (0.05) −0.08 (0.06)
Median (range) −0.08 (-0.18 to 0.02) −0.10 (-0.18 to 0.04)
UDIVA 60 cm 0.058
Mean±SD 0.10 (0.03) 0.12 (0.04)
Median (range) 0.10 (0.02 to 0.14) 0.12 (0.06 to 0.20)
BDCIVA 60 cm
Mean±SD 0.07 (0.03) 0.10 (0.03) 0.001
Median (range) 0.08 (0.00 to 0.08) 0.10 (0.04 to 0.18)
UNVA 40 cm 0.001
Mean±SD 0.26 (0.08) 0.14 (0.05)
Median (range) 0.24 (0.14 to 0.32) 0.14 (0.02 to 0.20)
BDCNVA 40 cm 0.001
Mean±SD 0.26 (0.05) 0.14 (0.04)
Median (range) 0.26 (0.16 to 0.36) 0.14 (0.06 to 0.20)
BDCIVA, best distance corrected intermediate visual acuity; BDCNVA, best distance corrected near visual acuity; BDCVA, best distance corrected 
visual acuity; UDVA, uncorrected distance visual acuity; UIVA, uncorrected intermediate visual acuity; UNVA, uncorrected near visual acuity.
Figure 1 Defocus curve. The defocus curve, according to visual acuity at several distances, presented significant differences 
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better outcomes in Symfony group and an opposite condi-
tion is pointed out at −2.50 D defocus threshold (p=0.001).
Objective quality of vision and CS
To assess objective quality of vision Strehl ratio, internal 
RMS and MTF cut- off at pupil size of 4 mm have been 
used (table 3).
Mean Strehl ratio was 0.17 (±0.05) for the Symfony 
group and 0.15 (±0.08) for the PanOptix group. No statis-
tically significant differences were found between groups 
(p=0.258). Mean internal RMS at 4 mm was 0.15 (±0.06) 
for the Symfony group and 0.18 (±0.06) for the PanOptix 
group, with a statistically significant difference between the 
two groups (p=0.024). CS was assessed by means of mean 
MTF cut- off evaluation: the Symfony group mean MTF cut- 
off was 34.25 (±11.8) c/deg, whereas PanOptix group had a 
mean MTF cut- off of 27.41 (±0.06) c/deg. Statistically signif-
icant difference was present between groups (p=0.041) with 
Symfony IOLs having the better results.
Subjective quality of vision
Subjective quality of vision was calculated from the NEI- 
RQL-42 score. Main outcome endpoints were the items 
‘clarity of vision’, ‘near vision’, ‘dependence on correction’ 
and ‘symptoms’ (table 4).
Clarity of vision mean score for Symfony IOLs was 92.01 
(±10.41), whereas PanOptix IOL achieved 88.75 (±18.53). 
Near vision mean score was 86.11 (±15.89) for Symfony IOLs 
and 90.81 (±16.00) for PanOptix IOLs. Dependence on 
correction mean score for Symfony IOLs was 62.96 (±35.37), 
while PanOptix IOLs scored 95.00 (±9.21). Symptoms’ score 
was 79.73 (±19.99) for Symfony IOLs and 75.75 (±16.09) for 
PanOptix IOLs. No statistically significant differences were 
reported between mean scores for the two groups of patients 
concerning any of these evaluation parameters.
DISCUSSION
Many patients undergoing cataract surgery demand a spec-
tacles independence in daily activities. In the ‘refractive 
cataract era’ a customised surgical intervention is suggested 
and many diffractive MIOLs are now available in order to 
solve pseudophakic presbyopia. In this paper both modern 
MIOLs (Symfony and PanOptix) have been studied with the 
largest and balanced cohort of patients, comparing them 
with a comprehensive analysis of objective and subjective 
parameters at 3 months outlining all different outcomes 
secondary to Symfony and PanOptix MIOLs implantations 
permitting the surgeon to lead a customised and aware 
choice. According to literature,9–12 no statistically significant 
difference was recorded between two groups when taking 
into account 4 m uncorrected and best- corrected distance 
visual acuity, with both groups achieving good results in 
terms of visual acuity and of postoperative spherical equiv-
alent (SE), and better results in UNVA and BDCNVA were 
found in favour of PanOptix group. In literature there is no 
consensus in outcome results at intermediate and quality of 
vision; the aim of this paper is to clarify the IOLs’ behaviour 
with a comprehensive study having numerous and balanced 
sample of patients.
As for the intermediate vision at 60 cm some authors agree 
with this study finding better results for Symfony IOL,10–12 
but not all of these authors find statistical significance 
between the groups, probably for the small and inhomo-
geneous sample of patients. In this paper that presents the 
most numerous, homogeneous and appropriate sample of 
population, patients implanted bilaterally with Symfony have 
a significantly better BDCIVA.
Table 3 Objective postoperative quality of vision
Postoperative quality of vision
A





(25 patients) P value
Strehl ratio 0.258
Mean (SD) 0.17 (0.05) 0.15 (0.08)
Median (range) 0.1 (0.001 to 0.272) 0.12 (0.07 to 0.4)
RMS 4 mm 
(μm)
0.024
Mean (SD) 0.15 (0.06) 0.18 (0.06)
Median (range) 0.18 (0.05 to 0.46) 0.2 (0.08 to 0.33)
MTF cut- off 0.041
Mean (SD) 34.25 (11.8) 27.41 (13.5)
Median 36.69 22.2
MTF, Modulation Transfer Function; RMS, root mean square.
Table 4 Subjective quality of vision by means of NEI- 
RQL-42 score
Subjective quality of vision NEI- RQL-42 score







Clarity of vision 92.01 (10.41) 88.75 (18.53)
91.66 (56.25 to 100) 100 (44.4 to 100)
Expectations 61.49 (36.44) 70.83 (43.10)
74 (0 to 100) 100 (0.00 to 100)
Near vision 86.11 (15.89) 90.81 (16.00)
83.33 (39.58 to 100) 91.75 (33.3 to 100)
Far vision 87.65 (13.18) 84.50 (14.90)
88.33 (45 to 100) 89.16 (39.98 to 100)
Diurnal 
fluctuations
80.71 (24.21) 82.98 (22.67)
87.50 (12.5 to 100) 93.75 (29.75 to 100)
Dependence on 
correction
62.96 (35.37) 95 (9.21)
75 (0 to 100) 100 (100 to 75)
Symptoms 75.75 (16.09) 79.73 (19.99)
79.83 (35 to 100) 91 (35.8 to 100)
Suboptimal 
correction
91.20 (18.33) 100 (0)
100 (50 to 100) 100 (100 to 100)
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Monaco et al in 2017, found better results in the interme-
diate vision (both BDCIVA and UIVA) for PanOptix IOL, 
with statistical significance in UIVA.13 This finding disagrees 
with the existing literature and it is important to emphasise 
that author performed the intermediate visual acuity at 67 
cm, which corresponds to the PanOptix intermediate focus. 
The remaining literature performed this evaluation at 60 
cm, which is the distance universally used for the evaluation 
of the intermediate visual acuity.
Knowledge of the behaviour of MIOL is essential to 
choose the specific implant compatible with patient’s needs: 
PanOptix IOL would be an optimal choice for patients who 
wish to see optimally at near range, while Symfony IOL is 
suitable for those who need good intermediate vision such 
as those who often use electronic devices such as computers, 
smartphones and tablets. The study of the defocus curve 
confirms the behaviour of these MIOLs and their main 
indications. Regarding the quality of vision (objective and 
subjective) both lenses achieve high levels of image quality 
with minimal disturbances. Comparing two groups, the 
Symfony IOL emerged as the best CS (cut- off MTF) and 
aberrometry (internal RMS 4 mm). Most of the existing 
literature reported no difference in CS and quality of vision 
using both objective and subjective evaluation methods,9 10 13 
in particular Mencucci and Andrè Lins De Medeiros found 
significantly better results in CS for Symfony IOL.11 14 In this 
study, having the largest and most homogeneous popula-
tion sample, an objective assessment of CS was used and the 
MTF cut- off and RMS were found to be statistically better 
for the Symfony IOL. Furthermore, it has already been 
shown that Symfony IOL performs CS in a way comparable 
to the monofocal.15 Discordant results were also found by 
Monaco et al in RMS at 5 mm, where quality of vision was 
higher for the PanOptix group.13 However, the author used 
a dynamic schiascopy difficult to compare with a Hartmann- 
Shack system and moreover he considered a 5 mm diameter 
instead of 4 mm of our sample. The objective outcomes were 
also confirmed in the NEI- RQL-42 scores where ‘clarity of 
vision’ and ‘Symptoms’ showed differences (although not 
statistically significant) in favour of the Symfony IOL group. 
Nevertheless, the superiority of Symfony IOLs in quality of 
vision does not guarantee the same results in ‘dependence of 
correction’ and ‘near vision’, where PanOptix IOLs achieved 
better subjective scores. To conclude, this study proves that 
every IOL has its different field of application that needs to 
be matched with each patient’s expectations and lifestyle to 
achieve the best satisfaction. A study with an adequate and 
homogeneous population court is essential to clarify the 
functioning of these IOLs.
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